SIC
TEVA icon

SJS Investment Consulting’s Teva Pharmaceuticals TEVA Stock Holding History

SJS Investment Consulting’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39K Hold
100
– – ﹤0.01% 1550
2026
Q1 		$3.01K Hold
100
– – ﹤0.01% 1175
2025
Q4 		$3.12K Buy
+100
New +$2.46K ﹤0.01% 1039
2022
Q1 		$1K Hold
130
– – ﹤0.01% 637
2021
Q4 		$1K Buy
+130
New +$1.17K ﹤0.01% 512

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

SJS Investment Consulting's TEVA Position: Q2 2026 in Review

SJS Investment Consulting held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 100 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

SJS Investment Consulting first reported a position in TEVA in Q4 2021 and has held it in 5 quarters since. 332 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • SJS Investment Consulting held 100 shares of Teva Pharmaceuticals worth $3.39K as of Q2 2026.
  • SJS Investment Consulting left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1550 holding.
  • SJS Investment Consulting first reported a position in Teva Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • 332 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.